Xiaodi Xu , Haoran Zhu , Qingbo Shao , Baiyu Chen , Jing Lin , Yang Gao , Zhenzhou He , Wei Fu , Wei Li
{"title":"Discovery, SAR, and molecular basis of (R)-1-((3R,4S)-3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-3-(3-fluorophenyl)-2-methylpropan-1-one as a novel potent analgesic","authors":"Xiaodi Xu , Haoran Zhu , Qingbo Shao , Baiyu Chen , Jing Lin , Yang Gao , Zhenzhou He , Wei Fu , Wei Li","doi":"10.1016/j.bmc.2025.118474","DOIUrl":"10.1016/j.bmc.2025.118474","url":null,"abstract":"<div><div>Opioid analgesics remain a cornerstone of pain management, among which μ-opioid receptor (MOR) agonists dominate clinical practice due to their well-established efficacy. However, dose related adverse effects (<em>e.g.</em>, respiratory depression, addiction potential) constrain their therapeutic utility, driving sustained efforts to develop novel MOR agonists with improved safety profiles. Building upon our previously identified lead compound <strong>FWB2</strong>, a series of 3-((dimethylamino)methyl)-4-(3-methoxyphenyl)piperidin-4-ol derivatives was designed <em>via</em> structure-based drug design (SBDD), synthesized, and systematically evaluated through comprehensive <em>in vitro</em> and <em>in vivo</em> pharmacological profiling. Systematic structure-activity relationship (SAR) exploration identified (<em>R,</em> (3<em>R,</em>4<em>S</em>))-<strong>6c</strong> as a novel and selective MOR agonist (MOR <em>K</em><sub><em>i</em></sub> = 0.9 nM, MOR: DOR: KOR = 1: 561.1: 188.3; MOR EC<sub>50</sub> = 89.9 nM), demonstrating potent antinociceptive activity (ED<sub>50</sub> = 1.63 mg/kg) in the hot plate model. Molecular docking studies elucidated the binding mode of (<em>R,</em>(3<em>R,</em>4<em>S</em>))-<strong>6c</strong> with the MOR, identifying its molecular interactions with four critical residues W318<sup>7.35</sup>, D147<sup>3.32</sup>, H54 and W293<sup>6.48</sup>, while delineating the structural features of the ligand-receptor binding pocket.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118474"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anjie S. Bispat , Fernanda C. Cardoso , Mahadhi Hasan , Callum E. Adams , Richard J. Lewis , Peter J. Duggan , Kellie L. Tuck
{"title":"Inhibition of N-type calcium channels by phenoxyanilide analogues","authors":"Anjie S. Bispat , Fernanda C. Cardoso , Mahadhi Hasan , Callum E. Adams , Richard J. Lewis , Peter J. Duggan , Kellie L. Tuck","doi":"10.1016/j.bmc.2025.118449","DOIUrl":"10.1016/j.bmc.2025.118449","url":null,"abstract":"<div><div>A series of <em>N,N</em>-dimethylated phenoxyanilide analogues were synthesised and evaluated for their activity at Ca<sub>V</sub>2.2 and Ca<sub>V</sub>3.2 channels. The SAR study conducted, highlighted that steric and hydrophobic interactions primarily enhanced the affinity for the Ca<sub>V</sub>2.2 channel, while an electron-rich aromatic phenoxy ring (R) favoured Ca<sub>V</sub>3.2 inhibition. Whilst the -CF<sub>3</sub> phenoxyanilide compounds exhibited a high potency for the Ca<sub>V</sub>2.2 channel, their low CNS MPO scores and high lipophilicity were indicative of a reduced likelihood of crossing the blood-brain barrier (BBB) and suboptimal physicochemical characteristics. The outcomes of this investigation provided valuable insights into the development of selective calcium channel inhibitors for the treatment of neuropathic pain, while building on previous SAR studies performed within the research group.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118449"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145322853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Runchu Li , Xiaoxu Yang , Wenjia Dan , Jiangkun Dai
{"title":"Natural product-derived antifungals against Candida albicans: Chemical diversity and mechanisms of action","authors":"Runchu Li , Xiaoxu Yang , Wenjia Dan , Jiangkun Dai","doi":"10.1016/j.bmc.2025.118435","DOIUrl":"10.1016/j.bmc.2025.118435","url":null,"abstract":"<div><div><em>Candida albicans</em> is a pathogenic fungus responsible for both superficial mucosal infections and life-threatening systemic candidiasis, presenting a substantial challenge to global health. The discovery of novel antifungal agents against <em>C. albicans</em> remains a critical priority in medicinal chemistry. Natural products and their derivatives have historically played a pivotal role in antifungal drug development. This review systematically summarizes recent advances in natural products exhibiting activity against <em>C. albicans</em> from 2020 to the first half of 2025, with an emphasis on their structural diversity including aldehydes, alkaloids, fatty acids, flavonoids, glycosides, peptides, phenylpropanoids, polyketides, tannins, and terpenoids. Furthermore, the antifungal mechanisms of these compounds are discussed, focusing on their interactions with critical targets such as the cell wall, cell membrane, virulence factors, and intracellular targets. By compiling these findings, this review aims to provide valuable insights and lead compounds to guide the design of next-generation antifungals against <em>C. albicans</em>.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118435"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wenjun Li , Junlong Chen , Yunyan Liu , Qizhi Chen , Yanjin Li , Fangzhou Linli , Sisi Feng , Xianggui Chen
{"title":"Sulfonium-stabilized anoplin cyclic peptides with enhanced electro-positivity for effective antimicrobial activity, stability, and biocompatibility","authors":"Wenjun Li , Junlong Chen , Yunyan Liu , Qizhi Chen , Yanjin Li , Fangzhou Linli , Sisi Feng , Xianggui Chen","doi":"10.1016/j.bmc.2025.118428","DOIUrl":"10.1016/j.bmc.2025.118428","url":null,"abstract":"<div><div>The overuse of antibiotics has highlighted the antimicrobial peptides (AMPs) as critical agents against pathogenic bacteria. However, natural AMPs like anoplin face significant limitations, including instability and suboptimal antimicrobial efficacy. Although previous studies have demonstrated the crucial role of stable secondary structures in enhancing antimicrobial activity, concerns have arisen regarding the increased hemolytic toxicity associated with hydrophobic side chains introduced by the RCM stapling strategy. To address this challenge, we propose a sulfonium-stabilized cyclization strategy that stabilizes peptide conformation through covalent cyclization and enhances cationic charge density via sulfur-based positive charges. Notably, the improved cationic charge could help to increase the peptide's antimicrobial activity while avoiding the enhancement of hemolytic toxicity. Experimental validation revealed that sulfonium-stabilized anoplin cyclic peptides (AP[5,9]-Ph) exhibited potent antibacterial activity, extended proteolytic stability, and preserved biocompatibility. Murine wound infection models demonstrated accelerated healing rates and reduced bacterial loads in treated groups. These findings suggest that sulfonium-stabilized anoplin cyclic peptides are promising candidates for novel antimicrobial agents. Moreover, the sulfonium-stabilized stapling strategy holds potential as a powerful approach for optimizing the bioactivity of natural antimicrobial peptides like anoplin, advancing the development of new antimicrobial agents.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118428"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145360024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
George A. Naclerio , Christopher S. Vennard , Kenneth I. Onyedibe , Dielson da S. Vieira , Nader S. Abutaleb , Marxa L. Figueiredo , Mohamed N. Seleem , Herman O. Sintim
{"title":"Halogenated N-(1,3,4-oxadiazol-2-yl) benzamides are effective eradicators of methicillin-resistant Staphylococcus aureus biofilms","authors":"George A. Naclerio , Christopher S. Vennard , Kenneth I. Onyedibe , Dielson da S. Vieira , Nader S. Abutaleb , Marxa L. Figueiredo , Mohamed N. Seleem , Herman O. Sintim","doi":"10.1016/j.bmc.2025.118437","DOIUrl":"10.1016/j.bmc.2025.118437","url":null,"abstract":"<div><div>Due to the ever-increasing threat of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), we have embarked on a campaign to discover novel antibacterial agents which are effective at eradicating both MRSA, as well as acting on pre-formed MRSA biofilms. Using the known scaffold of <em>N</em>-(1,3,4-oxadiazol-2-yl)benzamides, we performed a halogenation study which has led to the identification of <strong>HSGN-2241</strong>. This novel compound was found to effectively kill many multi-drug resistant Gram-positive clinical isolates in a bactericidal manner. The growth inhibition mechanism of <strong>HSGN-2241</strong> was found to be via potassium ion release and subsequent depolarization of the cell membrane. As an initial safety test, <strong>HSGN-2241</strong> was found to not lyse human red blood cells, so it is a promising lead compound for the treatment of bacterial infections caused by <em>Staphylococcus aureus.</em></div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118437"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145353157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Screening and identification of covalent Nrf2 activators with α,β-unsaturated imide structures","authors":"Yasuhiko Izumi , Norihiko Takeda , Shuzo Nishimoto , Honoka Niimi , Sayuri Ishizu , Natsumi Muneyasu , Yuto Takamatsu , Emi Mishiro-Sato , Keiko Kano , Kouya Yamaki , Takahiro Yamada , Yutaka Koyama , Masafumi Ueda","doi":"10.1016/j.bmc.2025.118454","DOIUrl":"10.1016/j.bmc.2025.118454","url":null,"abstract":"<div><div>The Kelch-like ECH-associated protein 1 (Keap1)–nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway is a central regulator of cellular defense mechanisms against oxidative stress. The pharmacological activation of this pathway has emerged as a promising strategy for the treatment of diseases such as neurodegeneration and inflammation. In this study, we performed a high-throughput luciferase reporter assay to screen the original compound library comprising small molecules synthesized at Kobe Pharmaceutical University. Initial screening identified KU-0016, KU-0017, and KU-0171 as moderate activators of the Nrf2 pathway. Furthermore, structural comparison revealed a common α,β-unsaturated imide motif, which led to the synthesis of KU-0017-based analogs for structure–activity relationship analysis. Among them, KU-0479 exhibited potent Nrf2 activation and low cytotoxicity. Further assays demonstrated that KU-0479 increased the intracellular glutathione (GSH) levels and protected cells from hydrogen peroxide–induced oxidative damage in a GSH-dependent manner. Moreover, LC–MS analysis confirmed the formation of mono-GSH adducts, and covalent docking simulations suggested covalent binding at the Cys151 residue of Keap1. These findings highlight KU-0479 as a synthetically accessible covalent Nrf2 activator with favorable redox-modulating properties and therapeutic potential.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118454"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145353155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Structure-based design, synthesis, and evaluation of tetrahydrotriazolothiazepine derivatives as novel 11β-hydroxysteroid dehydrogenase type 1 inhibitors","authors":"Yukinobu Numata , Toru Hasegawa , Makoto Mori , Tsuyoshi Shinozuka , Yuko Yamamoto , Masatoshi Honzumi , Chinami Kanayama , Atsushi Aoyagi , Manabu Abe , Yuka Ofune , Kanae Suzuki , Yuichiro Imamura , Chizuko Yahara , Wataru Obuchi , Ayako Moritomo , Mizuki Takahashi","doi":"10.1016/j.bmc.2025.118418","DOIUrl":"10.1016/j.bmc.2025.118418","url":null,"abstract":"<div><div>11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that converts cortisone to cortisol, and the therapeutic inhibition of this enzyme has attracted substantial attention for the treatment of various disorders including metabolic syndrome, cognitive decline, skin diseases, liver fibrosis, glaucoma, and osteoporosis. With the aim of developing a novel and potent 11β-HSD1 inhibitor, we designed and synthesized a series of tetrahydrotriazolothiazepine derivatives containing a sulfur atom in the seven-membered ring. An optimization study guided by structure-based drug design led to the discovery of compound <strong>3f</strong> as a potent and orally bioavailable 11β-HSD1 inhibitor. The oral administration of <strong>3f</strong> demonstrated good pharmacokinetic profiles and <em>in vivo</em> inhibition of 11β-HSD1 in mice and monkeys.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118418"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145311973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rong Li , Wei-Feng Zhang , Hui Lei , Fan-Bo Meng , Wenyi Liu , Rui Xiong , Hang Zhang , Yanjun Wang , Yingying Jiang , Guo-Bo Li , Li-Jiao Wang , Lingling Yang , Hua-Li Wang
{"title":"Design, synthesis and biological evaluation of novel glutaminyl cyclase inhibitors targeting the CD47-SIRPα axis in breast cancer cells","authors":"Rong Li , Wei-Feng Zhang , Hui Lei , Fan-Bo Meng , Wenyi Liu , Rui Xiong , Hang Zhang , Yanjun Wang , Yingying Jiang , Guo-Bo Li , Li-Jiao Wang , Lingling Yang , Hua-Li Wang","doi":"10.1016/j.bmc.2025.118469","DOIUrl":"10.1016/j.bmc.2025.118469","url":null,"abstract":"<div><div>Glutaminyl cyclase isoforms (gQC and sQC) are zinc-dependent metalloenzymes that catalyze the formation of <em>N</em>-terminal pyroglutamate (pE) in peptides and proteins. In human malignancies, gQC drives tumor immune evasion by enhancing CD47 pyroglutamylation, thereby amplifying its “don't eat me” signaling through interactions with SIRPα on immune cells. This establishes QC (particularly gQC isoform) as a compelling therapeutic target for cancer immunotherapy. In this study, we describe the structure-guided design and SAR optimization of a novel series of benzimidazole-based QC inhibitors aimed at disrupting the CD47-SIRPα immune checkpoint in breast cancer. Among these, compound <strong>30</strong> was identified as a potent dual inhibitor of both gQC and sQC, exhibiting nanomolar inhibitory activity with IC<sub>50</sub> values of 0.59 μM (gQC) and 0.83 μM (sQC). Molecular docking and 100 ns molecular dynamics simulations revealed that compound <strong>30</strong> with the catalytic zinc ion and forms multiple stabilizing hydrogen bonds within the QC active site, with simulations further confirming the stability of the binding mode. Biological evaluation demonstrated that compound <strong>30</strong> selectively disrupted the CD47-SIRPα interaction, significantly enhancing macrophage-mediated phagocytosis of tumor cells. These findings highlight compound <strong>30</strong> as a promising lead compound and validate QC catalytic inhibition as a potential therapeutic strategy to counteract immune evasion in breast cancer.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118469"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145413940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Machine learning in antiviral drug design","authors":"Anja Kolarič , Marko Jukič , Urban Bren","doi":"10.1016/j.bmc.2025.118426","DOIUrl":"10.1016/j.bmc.2025.118426","url":null,"abstract":"<div><div>Viral infections pose a significant health threat worldwide. Due to the high mutation rates of many viruses and their reliance on host cellular machinery, the development of effective antiviral therapies is particularly difficult. As a result, only a limited number of antiviral agents is currently available. In parallel to modern vaccines, traditional antiviral drug development is both time-consuming and costly, underscoring the need for faster, more efficient approaches. In recent years, particularly since the beginning of the COVID-19 pandemic, machine learning (ML) together with broader artificial intelligence (AI), have emerged as powerful methodologies for drug discovery and offer the potential to accelerate the identification and development of antiviral agents. This review examines the application of ML in the early stages of antiviral drug discovery, with a particular focus on recent studies where ML methods have successfully identified hit compounds with experimentally demonstrated activity in biological assays. By highlighting these successful case studies, the review illustrates the growing impact of ML in advancing the discovery of urgently needed novel antivirals.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118426"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pedro Augusto Lemos Santana, Rafael Christian de Matos, Ana Flávia Alvarenga Bitencourt, Vinícius Gonçalves Maltarollo, Marta Marques Gontijo de Aguiar, Renes Resende Machado, Renata Barbosa de Oliveira
{"title":"Design of arylfurans as potential FAAH inhibitors: therapeutic potential in pain management","authors":"Pedro Augusto Lemos Santana, Rafael Christian de Matos, Ana Flávia Alvarenga Bitencourt, Vinícius Gonçalves Maltarollo, Marta Marques Gontijo de Aguiar, Renes Resende Machado, Renata Barbosa de Oliveira","doi":"10.1016/j.bmc.2025.118471","DOIUrl":"10.1016/j.bmc.2025.118471","url":null,"abstract":"<div><div>The endocannabinoid system plays a critical role in regulating pathophysiological processes and represents a promising target for novel therapies aimed at neurodegenerative disorders. Anandamide (AEA) mediates its therapeutic effects, particularly in pain modulation; however, its clinical potential is constrained by rapid degradation via fatty acid amide hydrolase (FAAH). The keto-oxazolopyridine derivative OL-135 is a potent FAAH inhibitor (IC<sub>50</sub> = 4.7 nM). In this study, molecular docking simulations using three distinct protocols were performed to evaluate the binding modes of 44 arylfuran analogs of OL-135 at the FAAH enzyme binding site. These analyses identified several promising candidates, including analogs <strong>2</strong> and <strong>24</strong>, which were subsequently synthesized, characterized, and tested in experimental models of pain and inflammation in mice. Carrageenan-induced pain and paw edema were used to investigate the antinociceptive and anti-inflammatory activities. Also, hot plate test was employed to evaluate the antinociceptive activity. Compound <strong>2</strong> significantly reduced mechanical allodynia and acute paw edema induced by carrageenan. Compounds <strong>2</strong> and <strong>24</strong> (5, 25 and 100 mg/Kg, i.p.) reduced the nociceptive response in model of nociceptive pain (hot plate). The activity of compound 2 (100 mg/Kg) in the model of nociceptive pain was attenuated by previous administration of AM251 (4 and 8 mg/Kg, i.p.). Importantly, compound <strong>2</strong> demonstrated no adverse effects on key biochemical parameters indicative of cardiotoxicity, hepatotoxicity, or nephrotoxicity. These findings underscore the potential of arylfuran analogs as analgesic and anti-inflammatory agents, paving the way for further development of therapeutic molecules.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"132 ","pages":"Article 118471"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145413938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}